Polymorphisms in oxidative stress-related genes and mortality in breast cancer patients - Potential differential effects by radiotherapy?

Breast

Volumn 22, Issue 5, 2013, Pages 817-823

  Seibold, Petra ^a   Hall, Per ^b   Schoof, Nils ^b   Nevanlinna, Heli ^c   Heikkinen, Tuomas ^c   Benner, Axel ^a   Liu, Jianjun ^d   Schmezer, Peter ^a   Popanda, Odilia ^a   Flesch Janys, Dieter ^e   Chang Claude, Jenny ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d GENOME INSTITUTE OF SINGAPORE   (Singapore)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Breast cancer prognosis; Effect modification; Genetic variants; Oxidative stress; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MT2A GENE; NFE2L2 GENE; NQO1 GENE; ONCOGENE; OXIDATIVE STRESS; POPULATION BASED CASE CONTROL STUDY; POPULATION RESEARCH; POSTMENOPAUSE; PRDX1 GENE; PRDX6 GENE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCANDINAVIA; SINGLE NUCLEOTIDE POLYMORPHISM; THERAPY EFFECT; VALIDATION PROCESS;

BCSS; BREAST CANCER PROGNOSIS; BREAST CANCER-SPECIFIC SURVIVAL; CAT; CATALASE; CHEMOTHERAPY; CI; CONFIDENCE INTERVAL; CTX; CYBA; CYTOCHROME B-245 ALPHA POLYPEPTIDE; EFFECT MODIFICATION; ER; GENETIC VARIANTS; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE REDUCTASE; GLUTATHIONE S-TRANSFERASE ALPHA 1; GLUTATHIONE S-TRANSFERASE OMEGA; GPX1; GSR; GSTA1; GSTO1; HARDY-WEINBERG EQUILIBRIUM; HAZARD RATIO; HEAT SHOCK 27 KDA PROTEIN 1; HEME OXYGENASE 1; HMOX1; HR; HSPB1; HWE; LD; LINKAGE DISEQUILIBRIUM; MAF; MANGANASE SUPEROXIDE DISMUTASE, SEE ALSO SOD2; METALLOTHIONEIN 2A; MINOR ALLELE FREQUENCY; MNSOD; MPO; MT2A; MYELOPEROXIDASE; NAD(P)H; NAD(P)H DEHYDROGENASE QUINONE 1; NFE2L2; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE 3, ENDOTHELIAL NITRIC OXIDE SYNTHASE; NOS3; NQO1; NUCLEAR FACTOR ERYTHROID-DERIVED 2-LIKE 2; OESTROGEN RECEPTOR; OS; OVERALL SURVIVAL; OXIDATIVE STRESS; PEROXIREDOXIN; PR; PRDX; PROGESTERONE RECEPTOR; RADIOTHERAPY; RTX; SINGLE NUCLEOTIDE POLYMORPHISM; SNP; SOD1; SOD2; SUPEROXIDE DISMUTASE 1; SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL, SEE ALSO MNSOD; THIOREDOXIN 2, MITOCHONDRIAL; THIOREDOXIN REDUCTASE 1, CYTOSOLIC; THIOREDOXIN REDUCTASE 2, MITOCHONDRIAL; THIOREDOXIN, CYTOSOLIC; TNF; TUMOR NECROSIS FACTOR; TXN; TXN2; TXNRD1; TXNRD2;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CATALASE; FEMALE; GENOTYPE; HISTONE DEACETYLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PEROXIREDOXIN VI; PEROXIREDOXINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROSPECTIVE STUDIES; REPRESSOR PROTEINS;

EID: 84884160395     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2013.02.008     Document Type: Article

References (37)

1. Forouzanfar M.H., Foreman K.J., Delossantos A.M., Lozano R., Lopez A.D., Murray C.J.L., et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011, 378:1461-1484.
2. Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., Thurlimann B., Senn H.J. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747.
3. Riley P.A. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol 1994, 65:27-33.
4. Sun J., Chen Y., Li M., Ge Z. Role of antioxidant enzymes on ionizing radiation resistance. Free Radic Biol Med 1998, 24:586-593.
5. Saijo N. Critical comments for roles of biomarkers in the diagnosis and treatment of cancer. Cancer Treat Rev 2012, 38:63-67.
6. Udler M., Maia A.T., Cebrian A., Ahmed S., Pooley K.A., Greenberg D., et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. JClin Oncol 2007, 25:3015-3023.
7. Azzato E.M., Driver K.E., Lesueur F., Shah M., Greenberg D., Easton D.F., et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res 2008, 10:R47.
8. Azzato E.M., Pharoah P.D., Harrington P., Easton D.F., Greenberg D., Caporaso N.E., et al. Agenome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:1140-1143.
9. Ambrosone C.B., Sweeney C., Coles B.F., Thompson P.A., McClure G.Y., Korourian S., et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer. Cancer Res 2001, 61:7130-7135.
10. Fagerholm R., Hofstetter B., Tommiska J., Aaltonen K., Vrtel R., Syrjäkoski K., et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853.
11. Flesch-Janys D., Slanger T., Mutschelknauss E., Kropp S., Obi N., Vettorazzi E., et al. Risk of different histological types of postmenopausal breast cancer by type and regimen of menopausal hormone therapy. Int J Cancer 2008, 123:933-941.
12. Buck K., Zaineddin A.K., Vrieling A., Heinz J., Linseisen J., Flesch-Janys D., et al. Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer. Br J Cancer 2011, 105:1151-1157.
13. Vrieling A., Hein R., Abbas S., Schneeweiss A., Flesch-Janys D., Chang-Claude J. Serum 25-hydroxyvitamin D and postmenopausal breast cancer survival: a prospective patient cohort study. Breast Cancer Res 2011, 13:R74.
14. Li J., Humphreys K., Darabi H., Rosin G., Hannelius U., Heikkinen T., et al. Agenome-wide association scan on estrogen receptor-negative breast cancer. Breast Cancer Res 2010, 12:R93.
15. Seibold P., Hein R., Schmezer P., Hall P., Liu J., Dahmen N., et al. Polymorphisms in oxidative stress-related genes and postmenopausal breast cancer risk. Int J Cancer 2011, 129:1467-1476.
16. Therneau T.M., Grambsch P.M. Modeling survival data. Extending the Cox model 2000, Springer, New York, p. 75.
17. Schemper M., Smith T.L. Anote on quantifying follow-up in studies of failure time. Control Clin Trials 1996, 17:343-346.
18. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
19. Harrell F.E. Hmisc. R package version 3.9-2 2012.
20. Grambsch P.M., Therneau T.M. Proportional hazards test and siganostics based on weighted residuals. Biometrika 1994, 81:515-526.
21. Dupont W.D., Plummer W.D. Power and sample size calculations. A review and computer program. Control Clin Trials 1990, 11:116-128.
22. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005, 41:1690-1696.
23. Martin R.C., Ahn J., Nowell S.A., Hein D.W., Doll M.A., Martini B.D., et al. Association between manganese superoxide dismutase promoter gene polymorphism and breast cancer survival. Breast Cancer Res 2006, 8:R45.
24. Karihtala P., Mantyniemi A., Kang S.W., Kinnula V.L., Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003, 9:3418-3424.
25. Chang X.Z., Li D.Q., Hou Y.F., Wu J., Lu J.S., Di G.H., et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res 2007, 9:R76.
26. Woolston C.M., Storr S.J., Ellis I.O., Morgan D.A., Martin S.G. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer. Radiother Oncol 2011, 100:308-313.
27. Zhang B., Wang Y., Su Y. Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 2009, 286:154-160.
28. Morgan M.J., Liu Z.G. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell Res 2011, 21:103-115.
29. Anwar A., Dehn D., Siegel D., Kepa J.K., Tang L.J., Pietenpol J.A., et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. JBiol Chem 2003, 278:10368-10373.
30. Jamshidi M., Bartkova J., Greco D., Tommiska J., Fagerholm R., Aittomäki K., et al. NQO1 expression correlates inversely with NFkappaB activation in human breast cancer. Breast Cancer Res Treat 2012, 132:955-968.
31. Hubackova M., Vaclavikova R., Ehrlichova M., Mrhalova M., Kodet R., Kubackova K., et al. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int J Cancer 2012, 130:338-348.
32. Xu Z., Taylor J.A. SNPinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009, 37:W600-W605.
33. Bay B.H., Jin R., Huang J., Tan P.H. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood) 2006, 231:1516-1521.
34. Jin R., Chow V.T., Tan P.H., Dheen S.T., Duan W., Bay B.H. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 2002, 23:81-86.
35. Jin R., Huang J., Tan P.H., Bay B.H. Clinicopathological significance of metallothioneins in breast cancer. Pathol Oncol Res 2004, 10:74-79.
36. Zhang R., Zhang H., Wei H., Luo X. Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. JEnviron Pathol Toxicol Oncol 2000, 19:95-97.
37. El-Sharabasy M.M., El-Dosoky I., Horria H., Khalaf A.H. Elevation of glutathione, glutathione-reductase and nucleic acids in both normal tissues and tumour of breast cancer patients. Cancer Lett 1993, 72:11-15.